Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck Academic Article uri icon

Overview

MeSH Major

  • ErbB Receptors
  • Head and Neck Neoplasms
  • Quinazolines

abstract

  • Erlotinib was well tolerated in this heavily pretreated HNSCC population and produced prolonged disease stabilization; hence, further evaluation of its role in this tumor type is warranted.

publication date

  • December 2004

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2004.06.075

PubMed ID

  • 14701768

Additional Document Info

start page

  • 77

end page

  • 85

volume

  • 22

number

  • 1